Last reviewed · How we verify
LCAR- F33S cells intravenous infusion
LCAR- F33S cells intravenous infusion is a Biologic drug developed by Nanjing Legend Biotech Co.. It is currently in Phase 1 development.
At a glance
| Generic name | LCAR- F33S cells intravenous infusion |
|---|---|
| Sponsor | Nanjing Legend Biotech Co. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LCAR- F33S cells intravenous infusion CI brief — competitive landscape report
- LCAR- F33S cells intravenous infusion updates RSS · CI watch RSS
- Nanjing Legend Biotech Co. portfolio CI
Frequently asked questions about LCAR- F33S cells intravenous infusion
What is LCAR- F33S cells intravenous infusion?
LCAR- F33S cells intravenous infusion is a Biologic drug developed by Nanjing Legend Biotech Co..
Who makes LCAR- F33S cells intravenous infusion?
LCAR- F33S cells intravenous infusion is developed by Nanjing Legend Biotech Co. (see full Nanjing Legend Biotech Co. pipeline at /company/nanjing-legend-biotech-co).
What development phase is LCAR- F33S cells intravenous infusion in?
LCAR- F33S cells intravenous infusion is in Phase 1.